APELLIS PHARMACEUTICALS INC's ticker is APLS and the CUSIP is 03753U106. A total of 96 filers reported holding APELLIS PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,037,400 | -57.1% | 185,000 | +2.8% | 2.31% | -57.3% |
| Q2 2023 | $16,398,000 | +14.8% | 180,000 | -16.9% | 5.41% | +28.2% |
| Q1 2023 | $14,281,000 | -7.9% | 216,520 | -27.8% | 4.22% | -36.3% |
| Q4 2022 | $15,513,000 | -17.4% | 300,000 | +9.1% | 6.62% | +25.6% |
| Q3 2022 | $18,783,000 | +84.6% | 275,000 | +22.2% | 5.27% | -0.5% |
| Q2 2022 | $10,175,000 | -19.9% | 225,000 | -10.0% | 5.30% | +92.2% |
| Q1 2022 | $12,703,000 | -17.3% | 250,000 | -23.1% | 2.76% | -49.9% |
| Q4 2021 | $15,366,000 | +33.2% | 325,000 | -7.1% | 5.51% | +63.2% |
| Q3 2021 | $11,536,000 | +19.5% | 350,000 | +55.6% | 3.37% | +48.7% |
| Q1 2021 | $9,655,000 | -48.1% | 225,000 | -30.8% | 2.27% | -45.2% |
| Q4 2020 | $18,590,000 | -16.3% | 325,000 | -55.2% | 4.14% | -2.0% |
| Q4 2019 | $22,200,000 | +575.0% | 725,000 | +291.9% | 4.23% | +504.9% |
| Q3 2018 | $3,289,000 | -19.2% | 185,000 | 0.0% | 0.70% | -41.7% |
| Q2 2018 | $4,070,000 | – | 185,000 | – | 1.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 3,130,000 | $119,065,200 | 18.29% |
| EcoR1 Capital, LLC | 10,899,859 | $414,630,636 | 13.99% |
| Ally Bridge Group (NY) LLC | 181,805 | $6,915,862 | 8.12% |
| Avoro Capital Advisors LLC | 11,111,111 | $422,666,662 | 6.59% |
| ACUTA CAPITAL PARTNERS, LLC | 244,484 | $9,300,171 | 6.23% |
| Iron Triangle Partners LP | 880,000 | $33,475,200 | 4.89% |
| Cormorant Asset Management, LP | 2,000,000 | $76,080,000 | 4.44% |
| Octagon Capital Advisors LP | 675,000 | $25,677,000 | 3.94% |
| Logos Global Management LP | 750,000 | $28,530,000 | 3.81% |
| Boxer Capital, LLC | 1,726,000 | $65,657,040 | 3.50% |